Triple-negative breast cancer, as its name indicates, is defined as breast cancers that are negative for all three proteins, ER, PR, and HER2 (by immunohistochemistry or FISH), and accounts for approximately 15% of breast cancer patients worldwide. This evidence concerns the gene ERBB2 and breast cancer.